Palatin Technologies Inc. (PTN)
NASDAQ: PTNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PTN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $8.16M
- EPS (TTM)
- -$2.96
- Dividend yield
- None
- 52-week range
- 4.51 – 31.00
- Day range
- 4.56 – 4.99
- Volume / Avg
- 20.48K / 71.93K
- Beta
- —
- Shares outstanding
- 1.78M
52-week range
PTN stock today
Palatin Technologies (PTN) closed at $4.58 on Nov 20, down 7.10% (-$0.35), versus the S&P 500's 3.70% decline. Trading was light, with 20.48K shares changing hands, about 28% of the average daily volume. At this level, PTN sits near the bottom of its 52-week range of $4.51 to $31.00: 85.2% below the high, set on Dec 15, 2025 and 1.6% above the low.
PTN is down 70.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 79.9%. Palatin Technologies has posted a net loss over the last twelve months (EPS of -$2.96), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Palatin Technologies
Company profilePalatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases. licensing arrangements and other strategic transactions to advance and maximize the value of certain product candidates and program for the treatment of retinal diseases and with Altanispac Labs for PL9643 for the treatment of dry eye disease; and oral PL8177 for the treatment inflammatory bowel diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Carl Spana Ph.D.
- Headquarters
- Princeton, NJ
- Employees
- 25
- Website
- palatin.com
Financial highlights
Full financialsIn fiscal 2026, Palatin Technologies generated $8.8 million in revenue, up 0.0% from fiscal 2025. Palatin Technologies reported a net loss of $8.4 million, compared with a loss of $17.3 million a year earlier. Operating margin was -98.2%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $8.83M | $0 | $4.49M | $4.85M | $1.47M |
| Growth | — | -100.00% | -7.49% | +230.53% | +878.62% |
| Net income | $-8.38M | $-17.31M | $-29.74M | $-24.04M | $-36.20M |
| EPS (diluted) | $-2.96 | $-32.15 | $-101.16 | — | — |
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$53.50+1068.12%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 17, 2026
- EPS actual vs est.
- $4.26 vs $-0.32
- Surprise
- +1431.25%
PTN news
All PTN newsPalatin Technologies peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MBRXMoleculin Biotech Inc. | 7.74 | -2.40% | $8.22M | vs PTN |
| QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares | 1.29 | -9.15% | $8.29M | vs PTN |
| DAREDare Bioscience Inc. | 0.4074 | -9.87% | $8.01M | vs PTN |
| CLRBCellectar Biosciences Inc. | 0.797 | -11.50% | $8.00M | vs PTN |
| HINDVyome Holdings Inc. | 1.20 | -17.24% | $8.42M | vs PTN |
| PHIOPhio Pharmaceuticals Corp. | 0.656 | -8.25% | $7.84M | vs PTN |
| LEXXLexaria Bioscience Corp. | 4.03 | -10.24% | $8.49M | vs PTN |
| BIVIBioVie Inc. Class A | 0.80 | -12.07% | $8.58M | vs PTN |
Indexes, lists and sector
Palatin Technologies stock FAQ
What is Palatin Technologies's stock price today?
PTN last traded at $4.58 as of Nov 20, 4:00 PM EST, down 7.10% on the day. Prices are delayed at least 15 minutes.
Does Palatin Technologies pay a dividend?
No. Palatin Technologies does not currently pay a regular cash dividend.
Who is Palatin Technologies's CEO?
Dr. Carl Spana Ph.D. is the chief executive officer of Palatin Technologies Inc., which has about 25 employees.
Has PTN ever split its stock?
Yes. The most recent PTN stock split was a 1-for-50 split on Aug 12, 2025, one of 3 splits on record.
What is the PTN 52-week high?
The 52-week high for PTN is $31.00 and the 52-week low is $4.51. The stock is currently 85.2% below its high.